HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $25.00 price objective on the stock.

Milestone Pharmaceuticals Trading Down 6.3 %

Shares of NASDAQ:MIST opened at $1.63 on Friday. The company has a market cap of $86.92 million, a P/E ratio of -2.01 and a beta of 1.80. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The stock’s fifty day moving average price is $2.06 and its 200-day moving average price is $1.76.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp lifted its holdings in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals during the third quarter valued at $46,000. Finally, Northern Trust Corp increased its position in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after acquiring an additional 30,772 shares during the last quarter. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.